Anticancer Effects of Combined γ-Tocotrienol and PPARγ-Antagonist Treatment are Associated with a Suppression in Adipogenic Factor Expression


Breast Cancer

How to Cite

Abhita Malaviya, Parash Parajuli, & Paul W. Sylvester. (2014). Anticancer Effects of Combined γ-Tocotrienol and PPARγ-Antagonist Treatment are Associated with a Suppression in Adipogenic Factor Expression. Journal of Pharmacy and Nutrition Sciences, 4(1), 43–56.


Cancer cells reprogram their metabolism to meet the demands of accelerated growth. Glucose is the primary source of energy for cancer cells, but under conditions of high-energy demand lipids and free fatty acids become increasingly important. PPARγ is a member of the nuclear receptor superfamily and acts to regulate adipocyte differentiation and lipid metabolism. However, in many types of cancer, PPARγ activity is elevated in order to increase production of adipogenic factors [1, 2]. γ-Tocotrienol is an isoform of vitamin E that displays potent anticancer activity [3]. Previous studies have shown that the antiproliferative effects of combined treatment of ã-tocotrienol with PPAR?antagonists was associated with a reduction in PPARγ activity, expression of PPAR? and RXR, and suppression in Akt activation in MCF-7 and MBA-MB-231 human breast cancer cells [4]. The present study was conducted to determine the effects of combination treatment with these agents on adipogenic factor levels in rapidly proliferating human breast cancer cells. Western blot and qRT-PCR studies showed that combined treatment of ?-tocotrienol with PPAR?antagonists not only suppressed the adipogenic proteins, C/EBPγ and SREBP-1c, but also decreased their target lipogenic enzymes, ap2, FAS, and HMGCoR. However, treatment effects were also observed in PPARγ silenced breast cancer cells, indicating that these effects are mediated through PPARγ-independent mechanism. These findings suggest the combined treatment of γ-tocotrienol with PPARγ antagonist may have potential as a therapeutic strategy in the treatment of breast cancer.


Zaytseva YY, Wang X, Southard RC, Wallis NK, Kilgore MW. Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells. Mol Cancer 2008; 7: 90.

Robbins GT, Nie D. PPAR gamma, bioactive lipids, and cancer progression. Front Biosci 2012; 17: 1816-34.

Sylvester PW, Shah SJ. Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front Biosci 2005; 10: 699-709.

Malaviya A, Sylvester PW. Mechanisms Mediating the Effects of gamma-Tocotrienol When Used in Combination with PPARgamma Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer Cells. Int J Breast Cancer 2013; 2013: 101705.

Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocrine Rev 2011; 32(4): 550-70.

Nunn AV, Bell J, Barter P. The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance. Nuclear Receptor 2007; 5(1): 1.

Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002; 277(20): 17830-5.

Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 2004; 18(5): 528-40.

Edwards IJ, O'Flaherty JT. Omega-3 Fatty Acids and PPARgamma in Cancer. PPAR Res 2008; 2008: 358052.

Koh YK, Lee MY, Kim JW, Kim M, Moon JS, Lee YJ, et al. Lipin1 is a key factor for the maturation and maintenance of adipocytes in the regulatory network with CCAAT/enhancerbinding protein alpha and peroxisome proliferator-activated receptor gamma 2. J Biol Chem 2008; 283(50): 34896-906.

Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146(3): 408-20.

Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Ann Rev Cell Develop Biol 2000; 16: 145-71.

Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1995; 15(1): 351-7. 7799943

Chatterjee S, Szustakowski JD, Nanguneri NR, Mickanin C, Labow MA, Nohturfft A, et al. Identification of novel genes and pathways regulating SREBP transcriptional activity. PloS One 2009; 4(4): e5197.

Klopotek A, Hirche F, Eder K. PPAR gamma ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP- 2. Exp Biol Med (Maywood) 2006; 231(8): 1365-72.

Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7(10): 763-77.

Milde-Langosch K, Loning T, Bamberger AM. Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. Breast Cancer Res Treat 2003; 79(2): 175-85.

Yang Y, Morin PJ, Han WF, Chen T, Bornman DM, Gabrielson EW, Pizer ES. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 2003; 282(2): 132-7.

McIntyre BS, Briski KP, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 2000a; 224(4): 292-301.

McIntyre BS, Briski KP, Tirmenstein MA, Fariss MW, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 2000b; 35(2): 171-80.

Samant GV, Sylvester PW. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif 2006; 39(6): 563-74.

Shah S, Sylvester PW. Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp Biol Med (Maywood) 2004; 229(8): 745-55. http://www.ncbi.nlm.nih. gov/pubmed/15337828

Wali VB, Sylvester PW. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids 2007; 42(12): 1113-23.

Uto-Kondo H, Ohmori R, Kiyose C, Kishimoto Y, Saito H, Igarashi O, Kondo K. Tocotrienol suppresses adipocyte differentiation and Akt phosphorylation in 3T3-L1 preadipocytes. J Nutr 2009; 139(1): 51-7.

Song BL, DeBose-Boyd RA. Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase stimulated by delta- and gamma-tocotrienols. J Biol Chem 2006; 281(35): 25054-61.

Fang F, Kang Z, Wong C. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferatoractivated receptors. Mol Nutr Food Res 2010; 54(3): 345-52.

Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227(259): 680-5.

Sylvester PW, Birkenfeld HP, Hosick HL, Briski KP. Fatty acid modulation of epidermal growth factor-induced mouse mammary epithelial cell proliferation in vitro. Exp Cell Res 1994; 214(1): 145-53.

Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76(9): 4350-4.

Armoni M, Harel C, Karnieli E. Transcriptional regulation of the GLUT4 gene: from PPAR-gamma and FOXO1 to FFA and inflammation. Trends in Endocrinology and Metabolism: TEM 2007; 18(3): 100-7. pubmed/17317207

Chinetti G, Fruchart JC, Staels B. Peroxisome proliferatoractivated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammation research: official journal of the European Histamine Research Society [et al

Garber K. Energy deregulation: licensing tumors to grow. Science 2006; 312(5777): 1158-9.

Sylvester PW. Vitamin E and apoptosis. Vitam Horm 2007; 76: 329-56.

Nesaretnam K, Guthrie N, Chambers AF, Carroll KK. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 1995; 30(12): 1139-43.

Nesaretnam K, Stephen R, Dils R, Darbre P. Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 1998; 33(5): 461-9.

Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1(3): 465-70.

Wu Z, Bucher NL, Farmer SR. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol 1996; 16(8): 4128-36. 231409/

Zahnow CA. CCAAT/enhancer binding proteins in normal mammary development and breast cancer. Breast Cancer Research: BCR 2002; 4(3): 113-21.

Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996; 77(3): 474-82. 0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K

DeBose-Boyd RA. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res 2008; 18(6): 609-21.

Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, et al. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 1999; 19(8): 5495-503.

Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Investig 2002; 109(9): 1125-31.

Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 1994; 91(14): 6379-83.

Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, et al. Lipin 1 is an inducible amplifier of the hepatic PGC- 1alpha/PPARalpha regulatory pathway. Cell Metabol 2006; 4(3): 199-10.

Suviolahti E, Reue K, Cantor RM, Phan J, Gentile M, Naukkarinen J, et al. Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism. Human Mol Genet 2006; 15(3): 377-86.

Sim FJ, Lang JK, Ali TA, Roy NS, Vates GE, Pilcher WH, Goldman SA. Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation. Glia 2008; 56(9): 954-62.

Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343(6257): 425-30.

Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004; 229(7): 567-85. http://www.ncbi.nlm.nih. gov/pubmed/15229351

Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. J Biol Chem 1993; 268(15): 11230-8. 8388388

Wu Z, Xie Y, Bucher NL, Farmer SR. Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev 1995; 9(19): 2350-63.

Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7(6): 489-503.

Li H, Lu Q, Dong LH, Xue H, Zhou HY, Yang HJ. [Expression of fatty acid binding protein in human breast cancer tissues

Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7(1): 48-52.

Vernochet C, Milstone DS, Iehle C, Belmonte N, Phillips B, Wdziekonski B, et al. PPARgamma-dependent and PPARgamma-independent effects on the development of adipose cells from embryonic stem cells. FEBS Lett 2002; 510(1-2): 94-8.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2014 Abhita Malaviya, Parash Parajuli , Paul W. Sylvester